Overview

KSH01-R02-101 Solid Tumors

Status:
Not yet recruiting
Trial end date:
2027-10-11
Target enrollment:
Participant gender:
Summary
1. . safety and tolerance 2. . objective response rate
Phase:
Early Phase 1
Details
Lead Sponsor:
TCRx Therapeutics Co.Ltd